Molecular Mechanisms and Therapeutic Strategies in Parkinson's Disease: From Pathogenic Signaling to Drug Development.
Level 5 - mechanism / opinion, no new human data
Narrative review of molecular mechanisms and therapeutic strategies without systematic search methodology or primary data.
PubMed 42509706 · doi:10.2174/011570159X457429260706102249
What was done
This review summarized the molecular mechanisms, pathogenic signaling pathways, and biomarkers associated with Parkinson's disease (PD). It outlined existing symptomatic pharmacological options and reviewed emerging therapeutic candidates in clinical development aimed at disease modification.
What was found
The abstract reports no quantitative data or numerical findings. It qualitatively notes that PD has a prolonged prodromal phase lacking sensitive and specific early diagnostics, that current symptomatic treatments suffer from waning efficacy and motor complications over time, and that disease-modifying therapies remain unavailable.
Why it matters
It synthesizes current understanding of PD molecular pathogenesis with translational pipelines to highlight targets for disease-modifying drug development.
Limits
As a narrative review, it presents no new experimental or human clinical trial data, reports no quantitative effect sizes or numbers in the abstract, and does not specify systematic literature search criteria.
Cited by
- supports Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease.